ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Predictive model for clear cell renal cell carcinoma: a novel model integrating sunitinib resistance and prognosis related genes and clinical factors.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Interferon-induced transmembrane (IFITM) proteins at the tumour-immune interface: A four-axis framework for their context-dependent roles.Clinical and translational medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeSunitinib serves as the primary treatment for clear cell renal cell carcinoma (ccRCC). However, patients frequently develop resistance to it over time. Early prediction of sunitinib resistance and ccRCC prognosis is beneficial for optimizing clinical treatment. Therefore, we aimed to identify key genes associated with ccRCC sunitinib resistance and prognosis and develop a Clinical Gene Prognostic Nomogram Model (CGPNM) to assess drug sensitivity, treatment response, and survival outcomes in patient groups stratified by CGPNM nomogram scores.
methodsKey genes associated with sunitinib resistance and ccRCC prognosis were identified using weighted gene coexpression network analysis (WGCNA), differential gene expression analysis, and Cox regression analysis. Single-cell RNA sequencing (RNA-seq) analysis and gene set enrichment analysis (GSEA) revealed the expression patterns of these genes, and clinical factors were subsequently incorporated into the gene prognosis model (GPM) to develop a clinically-genetic prognosis nomogram model (CGPNM). Patients were divided into low risk and high risk groups based on the nomogram scores derived. Drug sensitivity, treatment response, and survival outcomes were assessed in patients in different risk groups.
resultsInterferon-induced transmembrane protein 1 (IFITM1), inositol monophosphatase 2 (IMPA2), and potassium calcium-activated channel subfamily N member 3 (KCNN3) are closely linked to sunitinib resistance and prognosis in clear cell renal cell carcinoma (ccRCC), each exhibiting distinct expression patterns: IFITM1 is expressed in lymphocytes, IMPA2 in tumor/epithelial cells, and KCNN3 in endothelial cells. Using these genes, the GPM was developed to predict drug resistance and prognosis in ccRCC patients. Furthermore, CGPNM models developed for key genes and clinical factors showed that patients with low or high CGPNM scores showed significant differences in drug sensitivity to chemotherapy and targeted drugs, and had different responses to chemotherapy, immunotherapy, and targeted therapy.
conclusionIFITM1, IMPA2 and KCNN3 emerged as key genes influencing sunitinib resistance and prognosis in ccRCC patients. The CGPNM, integrating genetic and clinical factors, effectively predicts survival and drug sensitivity among ccRCC patients, demonstrating robust performance. This model holds promise as a reliable tool for guiding clinical medication in ccRCC.
Indexed as
Identifiers
42020680What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.